Tempest Therapeutics (NASDAQ:TPST) Lowered to Hold Rating by Zacks Research

Tempest Therapeutics (NASDAQ:TPST) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Separately, Wall Street Zen lowered Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tempest Therapeutics has a consensus rating of “Reduce”.

Tempest Therapeutics Trading Down 12.4%

Shares of TPST opened at $1.83 on Thursday. The firm has a market cap of $26.24 million, a price-to-earnings ratio of -0.30 and a beta of -1.75. The stock has a 50 day moving average of $1.94 and a 200-day moving average of $3.35. Tempest Therapeutics has a 52 week low of $1.50 and a 52 week high of $12.23.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Friday, May 15th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($0.28) by ($2.25). On average, sell-side analysts predict that Tempest Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Activity at Tempest Therapeutics

In other news, CEO Matthew Angel bought 231,482 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The stock was bought at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer owned 231,482 shares in the company, valued at $500,001.12. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 6.28% of the company’s stock.

Institutional Trading of Tempest Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Sabby Management LLC bought a new stake in shares of Tempest Therapeutics in the 4th quarter worth approximately $513,000. Vanguard Group Inc. lifted its holdings in shares of Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after purchasing an additional 27,952 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics in the 4th quarter worth approximately $33,000. Institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.